Reducing cardiovascular morbidity and mortality from hypertension in end-stage renal disease

Michael L. Picton, Robert N. Foley

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Hypertension typically worsens with declining renal function, and is an almost universal feature of end-stage renal disease. Treating hypertension clearly reduces the likelihood of cardiovascular disease in nonrenal populations, with greater absolute benefit in those who have greater severity of underlying cardiovascular disease. Patients with chronic renal diseases are at enormous cardiovascular risk. Although our approach to hypertension in patients with early renal insufficiency has become more aggressive, the rationale has switched over the past decade from cardiovascular risk reduction to slowing the loss of renal function. Reliance on observational studies, especially using mortality as the outcome, has not allowed a consistent, rational approach to the treatment of hypertension in dialysis patients. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)497-500
Number of pages4
JournalCurrent opinion in nephrology and hypertension
Issue number5
StatePublished - Sep 18 2000


Dive into the research topics of 'Reducing cardiovascular morbidity and mortality from hypertension in end-stage renal disease'. Together they form a unique fingerprint.

Cite this